Developer docs
API playgroundTry for free, no card

Search company profiles

Lutonix

Full company profile

uuid000jmc7

Namestring
Lutonix
Legal namestring
Becton, Dickinson and Company
Websiteurl
lutonix.com
Company typeenum
Public
Founded yearint
1897
Descriptiontext

Lutonix is a Maple Grove, Minnesota-based medical device company founded in 2007 that develops drug-coated balloon (DCB) catheters for peripheral vascular intervention. Its lead product, the Lutonix DCB, delivers paclitaxel to the arterial wall during a single, short inflation, targeting the femoropopliteal and broader peripheral artery disease market served by interventional cardiologists and vascular surgeons. The company is privately held, operates with 11–50 employees, and is headquartered at lutonix.com.

Lutonix's core technology is a proprietary paclitaxel-coated balloon catheter platform in which the anti-restenotic drug is transferred to the vessel wall during balloon expansion, eliminating the need for a permanent implant. The platform relies on drug-coating formulation know-how, balloon mechanics, and combination-product (drug-device) engineering. The firm has been backed by a syndicate of healthcare-specialist venture investors, having raised approximately $35 million across three financing rounds between 2007 and 2010 (a $5M founding round in April 2007, a $20M Series 2 led by Versant Ventures in October 2008 with Delphi Ventures, RiverVest, and U.S. Venture Partners, and a $10M Series 3 in December 2010).

Lutonix's revenue model is typical of an early-commercial, single-product Class III combination-product device company: unit sales of the DCB catheter to hospitals, cath labs, and ambulatory surgery centers, typically procured through group purchasing organizations and specialty distribution channels. Pricing details, contract structures, and named end customers are not disclosed in the available input data. The firm operates as a standalone private entity in the provided sources, with Jay W. Schmelter listed as a director on its board.

Short descriptiontext

Lutonix develops drug-coated balloon catheters that deliver paclitaxel to arterial walls during a single short inflation for peripheral vascular intervention. Founded in 2007 in Maple Grove, Minnesota, the company serves interventional cardiologists and vascular surgeons treating peripheral artery disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew Hope, United States
HQ citystring
New Hope
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
drug-coated balloon, paclitaxel delivery, peripheral vascular intervention, balloon catheter, endovascular therapy
Industry1 code
PRIMARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Peripheral Vascular Intervention Devices
Cost components5 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 12 records shown
1BD Pyxis
Description

Automated dispensing solutions and pharmacy technologies system for medication availability, security and control.

bd.com
+11 more records
Core offering1 text field

Lutonix develops the Lutonix DCB, a drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. The product combines balloon angioplasty mechanics with localized drug delivery to treat peripheral arterial disease, and is sold as a medical device to hospitals and interventional clinicians.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Lutonix DCB (Drug-Coated Balloon Catheter)
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Penumbra's peripheral vascular thrombectomy and embolization devices compete in the same PAD treatment pathway as Lutonix DCB, addressing overlapping patient populations.

TypeBroad incumbent
Description

BD owns Lutonix via the C.R. Bard acquisition and is the parent company commercializing the product globally; it is the broad incumbent that controls Lutonix's commercial roadmap and distribution.

TypeEmerging player
Description

AngioDynamics offers peripheral thrombectomy and ablation products that are complementary/competitive in PAD treatment pathways where Lutonix DCB is also used.

TypeDirect peer
Description

Medtronic markets the IN.PACT Admiral drug-coated balloon, the leading paclitaxel DCB in the femoropopliteal segment and Lutonix DCB's most direct head-to-head competitor in peripheral vascular intervention.

TypeBroad incumbent
Description

Abbott competes in peripheral vascular intervention via drug-eluting stents (Xience Sierra) and other endovascular devices, providing an overlapping but broader portfolio versus the Lutonix DCB focus.

TypeBroad incumbent
Description

Cardinal Health distributes and supplies peripheral vascular devices and consumables, providing an indirect but adjacent competitor/distributor relationship to Lutonix within hospital vascular service lines.

TypeDirect peer
Description

Philips sells the Stellarex DCB in peripheral vascular disease and competes head-to-head with Lutonix for femoropopliteal and AV fistula share via its image-guided therapy division.

TypeEmerging player
Description

SurModics develops proprietary drug-coating technology used in third-party DCB programs, making it a comparable emerging player in the DCB enabling-technology space adjacent to Lutonix's paclitaxel delivery platform.

TypeBroad incumbent
Description

Teleflex operates a broad vascular and interventional access portfolio (including Arrow and specialty catheters) that overlaps with Lutonix's peripheral intervention customers and call points.

TypeDirect peer
Description

Boston Scientific offers the Ranger DCB and a broad peripheral vascular portfolio, competing directly with Lutonix DCB in femoropopliteal interventions and AV access.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lutonix

Peripheral Vascular Intervention Deviceslutonix.com

Lutonix develops drug-coated balloon catheters that deliver paclitaxel to arterial walls during a single short inflation for peripheral vascular intervention. Founded in 2007 in Maple Grove, Minnesota, the company serves interventional cardiologists and vascular surgeons treating peripheral artery disease.

What Lutonix does

Lutonix is a Maple Grove, Minnesota-based medical device company founded in 2007 that develops drug-coated balloon (DCB) catheters for peripheral vascular intervention. Its lead product, the Lutonix DCB, delivers paclitaxel to the arterial wall during a single, short inflation, targeting the femoropopliteal and broader peripheral artery disease market served by interventional cardiologists and vascular surgeons. The company is privately held, operates with 11–50 employees, and is headquartered at lutonix.com.

Lutonix's core technology is a proprietary paclitaxel-coated balloon catheter platform in which the anti-restenotic drug is transferred to the vessel wall during balloon expansion, eliminating the need for a permanent implant. The platform relies on drug-coating formulation know-how, balloon mechanics, and combination-product (drug-device) engineering. The firm has been backed by a syndicate of healthcare-specialist venture investors, having raised approximately $35 million across three financing rounds between 2007 and 2010 (a $5M founding round in April 2007, a $20M Series 2 led by Versant Ventures in October 2008 with Delphi Ventures, RiverVest, and U.S. Venture Partners, and a $10M Series 3 in December 2010).

Lutonix's revenue model is typical of an early-commercial, single-product Class III combination-product device company: unit sales of the DCB catheter to hospitals, cath labs, and ambulatory surgery centers, typically procured through group purchasing organizations and specialty distribution channels. Pricing details, contract structures, and named end customers are not disclosed in the available input data. The firm operates as a standalone private entity in the provided sources, with Jay W. Schmelter listed as a director on its board.

Lutonix firmographics

Firmographics
Name
Lutonix
Legal name
Becton, Dickinson and Company
Website
https://lutonix.com
Company type
Public
Founded year
1897
Operating status
Operating
Headcount range
1–10 employees
Short description
Lutonix develops drug-coated balloon catheters that deliver paclitaxel to arterial walls during a single short inflation for peripheral vascular intervention. Founded in 2007 in Maple Grove, Minnesota, the company serves interventional cardiologists and vascular surgeons treating peripheral artery disease.
Ownership category
akta.pro rank

Lutonix industry classification

Industry
Product category
Peripheral Vascular Intervention Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Drug-coated balloon
  • Paclitaxel delivery
  • Peripheral vascular intervention
  • Balloon catheter
  • Endovascular therapy

Where Lutonix is headquartered

Location

Headquarters

HQ city
New Hope
HQ country
United States
HQ region
North America

Markets served

Lutonix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Lutonix product offering

Product offering

Core offering

Lutonix develops the Lutonix DCB, a drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. The product combines balloon angioplasty mechanics with localized drug delivery to treat peripheral arterial disease, and is sold as a medical device to hospitals and interventional clinicians.

Differentiator

Problem solved

Functional benefit

Brands

  • BD Pyxis: Automated dispensing solutions and pharmacy technologies system for medication availability, security and control.
  • BD ChloraPrep
  • BD Nexiva
  • BD HemoSphere Alta
  • BD Aptra
  • PureWick
  • Rotarex
  • Phasix
  • Magic3 Go
  • VitaWave Plus
  • Bardex I.C.
  • BD Hypak

Products and services

  • Lutonix DCB (Drug-Coated Balloon Catheter)

Companies that use Lutonix

Customer profile

Ideal customer profiles1 record

Lutonix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Lutonix partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

Lutonix competitors and assessment

Company assessment

Emerging players

  • Penumbra: Penumbra's peripheral vascular thrombectomy and embolization devices compete in the same PAD treatment pathway as Lutonix DCB, addressing overlapping patient populations.
  • AngioDynamics: AngioDynamics offers peripheral thrombectomy and ablation products that are complementary/competitive in PAD treatment pathways where Lutonix DCB is also used.
  • SurModics: SurModics develops proprietary drug-coating technology used in third-party DCB programs, making it a comparable emerging player in the DCB enabling-technology space adjacent to Lutonix's paclitaxel delivery platform.

Broad incumbents

  • Becton, Dickinson and Company (BD): BD owns Lutonix via the C.R. Bard acquisition and is the parent company commercializing the product globally; it is the broad incumbent that controls Lutonix's commercial roadmap and distribution.
  • Abbott Vascular: Abbott competes in peripheral vascular intervention via drug-eluting stents (Xience Sierra) and other endovascular devices, providing an overlapping but broader portfolio versus the Lutonix DCB focus.
  • Cardinal Health: Cardinal Health distributes and supplies peripheral vascular devices and consumables, providing an indirect but adjacent competitor/distributor relationship to Lutonix within hospital vascular service lines.
  • Teleflex: Teleflex operates a broad vascular and interventional access portfolio (including Arrow and specialty catheters) that overlaps with Lutonix's peripheral intervention customers and call points.

Direct peers

  • Medtronic: Medtronic markets the IN.PACT Admiral drug-coated balloon, the leading paclitaxel DCB in the femoropopliteal segment and Lutonix DCB's most direct head-to-head competitor in peripheral vascular intervention.
  • Philips (Philips IGTD): Philips sells the Stellarex DCB in peripheral vascular disease and competes head-to-head with Lutonix for femoropopliteal and AV fistula share via its image-guided therapy division.
  • Boston Scientific: Boston Scientific offers the Ranger DCB and a broad peripheral vascular portfolio, competing directly with Lutonix DCB in femoropopliteal interventions and AV access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Lutonix social profiles

Digital presence

Lutonix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lutonix leadership team

Management profile

Number of profiles

Profiles1 record

Lutonix funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lutonix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lutonix

What does Lutonix do?

Lutonix develops the Lutonix DCB, a drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. The product combines balloon angioplasty mechanics with localized drug delivery to treat peripheral arterial disease, and is sold as a medical device to hospitals and interventional clinicians.

Is Lutonix a public or private company?

Lutonix is a public company. It is classified as corporate owned and is currently operating.

When was Lutonix founded?

Lutonix was founded in 1897. It employs 1 to 10 people.

Where is Lutonix based?

Lutonix is headquartered in New Hope, United States, in the North America region.

Who are Lutonix's main competitors?

Emerging players on record are Penumbra, AngioDynamics and SurModics. Broad incumbents are Becton, Dickinson and Company (BD), Abbott Vascular, Cardinal Health and Teleflex. Direct peers are Medtronic, Philips (Philips IGTD) and Boston Scientific.

Does Lutonix have an API?

No public API is recorded for Lutonix.

What industry is Lutonix in?

Lutonix's product category is Peripheral Vascular Intervention Devices. Its primary akta.pro industry code is HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MedicaltubingandextrusionFDA panel votes against BD Lutonix drug-coated balloon for below-the-kneeAn FDA advisory panel voted 15-2 against a favorable recommendation for BD's Lutonix drug-coated balloon for below-the-knee use, also voting 15-2 against effectiveness and 14-3 against benefits outweighing risks. The panel cited study design challenges in the pivotal trial. The FDA had denied approval in 2019 over a potential mortality signal.BioWorldMissing data, lack of operator blinding among issues that sidetrack Lutonix PMAA U.S. FDA advisory committee voted 14 nays to 3 ayes that the benefits of the Lutonix 014 drug-coated balloon do not outweigh the risks. The panel cited missing data and lack of operator blinding as key issues, leaving the sponsor to negotiate next steps with the FDA.VascularnewsParticulate embolisation after femoral artery treatment with DCBsA preclinical study compared the embolic safety of three drug-coated balloons—Lutonix, IN.PACT Admiral, and Stellarex—along with the Ranger DCB, finding that all devices produced downstream paclitaxel emboli in a porcine model. The research indicated varying degrees of non-target tissue effects among the devices, with IN.PACT showing higher levels of embolic debris compared to Stellarex and Ranger. These findings suggest potential risks associated with different DCB technologies that require further clinical evaluation.GlobeNewswireIN.PACT(TM) Falcon Is the Globally Preferred Drug-Coated Balloon Followed by SeQuent(R) Please and Lutonix(R) Survey IndicatesA global survey of interventional cardiologists found that IN.PACT Falcon is the preferred drug-coated balloon, with SeQuent Please leading in Europe and Lutonix in the U.S. Price was the most significant drawback, and DCB availability was the major reason for choosing FFR guidewires.